Delcath Systems, Inc. (DCTH) key performance indicators and operating metrics (7 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization | 3.4M | FY2026-Q1 |
| Active U.S. Treatment Centers | 29.00 | FY2026-Q1 |
| Gross Margin (Guidance Midpoint) | 85.00 percent | FY2026-Q1 |
| ChemoSat Product Revenue (Europe) | 1.7M | FY2026-Q1 |
| HEPZATO Kit Revenue (United States) | 23.3M | FY2026-Q1 |
| Active Treatment Centers | 28.00 | FY2025-Q4 |
| U.S. Centers Accepting Referrals | 10.00 | FY2025-Q2 |
Back to DCTH overview · DCTH earnings · DCTH holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.